Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II
https://doi.org/10.18008/1816-5095-2020-4-676-682
Abstract
Topical and systemic carbonic anhydrase inhibitors (CAIs) are widely used in the treatment of glaucoma for reducing intraocular pressure. This part of the review describes the characteristics of systemic CAIs, their side effects and the ways to overcome them, as well as contraindications. The use of CAIs during pregnancy is considered. Particular attention is paid to the antioxidant activity of CAIs and the promising development of hybrid forms based on the existing CAIs as a part of a multipurpose glaucoma treatment strategy.
About the Author
N. I. Kurysheva
The Department of Eye Diseases at the Medical Biological University of Innovations and Continuing Education of the A.I. Burnasyan Federal Medical Biophysical Center of the Federal Medical Biological Agency (FMBA);
Diagnostic Department of the Ophthalmological Center of FMBA of Russia, Clinical Hospital No. 86
Russian Federation
Russian Federation
MD., Professor, head of the consultative and diagnostic department,
15 Gamalei str., Moscow, 123098
References
1. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a doubleblind, prospective study. Am. J. Respir. Crit. Care Med. 2006 Jan 15;173(2):234–237. DOI: 10.1164/rccm.200507-1035OC
2. Van Berkel M.A., Elefritz J.L. Evaluating off-label uses of acetazolamide. Am J Health Syst Pharm. 2018 Apr 15;75(8):524–531. DOI: 10.2146/ajhp170279
3. Leaf D.E., Goldfarb D.S. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 2007 Apr;102(4):1313– 1322. DOI: 10.1152/japplphysiol.01572.2005
4. Supuran C.T. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(4):423–431. DOI: 10.1517/17425255.2016.1154534
5. Masini E., Carta F., Scozzafava A., Supuran C.T. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):705–716. DOI: 10.1517/13543776.2013.794788
6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Oct 2, 2017. Carbonic Anhydrase Inhibitors. PMID: 31643176
7. Ghorai S., Pulya S., Ghosh K., Panda P., Ghosh B., Gayen S. Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents. Bioorg. Chem. 2020 Jan;95:103557. DOI: 10.1016/j.bioorg.2019.103557
8. Her Y., Kil M.S., Park J.H., Kim C.W., Kim S.S. Stevens-Johnson syndrome induced by acetazolamide. J. Dermatol. 2011 Mar;38(3):272–275. DOI: 10.1111/j.13468138.2010.00921.x
9. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S155–S162. DOI: 10.1016/s0039-6257(99)00107-1
10. Silver L.H. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44(Suppl 2):S141–S145. DOI: 10.1016/s0039-6257(99)00111-3
11. Michaud J.E, Friren B. International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–243. DOI: 10.1016/s0002-9394(01)00974-6
12. Barnebey H., Kwok S.Y. Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204–1212. DOI: 10.1016/s0149-2918(00)83063-5
13. Auger G.A., Raynor M., Longstaff S. Patient perspectives when switching from Cosopt® (dorzolamide-timolol) to AzargaTM (brinzolamide-timolol) for glaucoma requiring multiple drug therapy. Clin Ophthalmol. 2012;6:2059–2062. DOI: 10.2147/OPTH.S33254
14. Manni G., Denis P., Chew P. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with openangle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293–300. DOI: 10.1097/IJG.0b013e31818fb434
15. Newman-Casey P., Niziol L., Gillespie B. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study Ophthalmology 2020 (article in press). DOI: 1016/j.ophtha.2019.10.022 1 ISSN 0161-6420/19
16. Robin A., Grover D. Compliance and adherence in glaucoma management Indian J Ophthalmol. 2011;59(Suppl 1):S93–S96. DOI: 10.4103/0301-4738.73693
17. Djafari F., Lesk M.R., Harasymowycz P.J., Desjardins D., Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238–243. DOI: 10.1097/IJG.0b013e3181815421
18. Altafini R., Scherzer M., Frezzotti P. Brinzolamide 1%/timolol versus dorzolamide 2%/ timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clinical Ophthalmology 2015;9:2263–2270. DOI: 10.2147/OPTH.S88891
19. Lanzl I., Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291–298. DOI: 10.2147/OPTH.S16355
20. Hutnik С., Neima D., Ibrahim N. Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free COSOPT®) in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology 2010;4:581–590.
21. Kwon J., Heo J., Kim H., Song J. Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/ timolol Korean J Ophthalmol 2015;29(5):344–350. DOI: 10.3341/kjo.2015.29.5.344
22. Pinto L., Vandewalle E., Gerlier L., Stalmans I. Improvement in Glaucoma Patient Quality of Life by Therapy Switch to Preservative-Free Timolol/Dorzolamide Fixed Combination Ophthalmologica 2014;231:166–171. DOI: 10.1159/000356468
23. Ozawa H., Azuma E., Shindo K., Higashigawa M., Mukouhara R., Komada Y. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr. 2001;160(5):321–322. DOI: 10.1007/pl00008441
24. Worsham F. Jr, Beckman E.N., Mitchell E.H. Sacrococcygeal teratoma in a neonate association with maternal use of acetazolamide. JAMA 1978;240 (3):251–252.
25. Weaver T.E., Scott W.J. Jr. Acetazolamide teratogenesis: interaction of maternal metabolic and respiratory acidosis in the induction of ectrodactyly in C57BL/6J mice. Teratology 1984;30(2):195–202. DOI: 10.1002/tera.1420300207
26. Sethi H.S., Naik M., Gupta V.S. Management of glaucoma in pregnancy: risks and choices, a dilemma? Int J Ophthalmol 2016;9(11):1684–1690. DOI: 10.18240/ ijo.2016.11.24
27. Tangamornsuksan W., Lohitnavy M. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenomics J. 2019 Jun;19(3):286–294. DOI: 10.1038/s41397-018-0052-2
28. Sweeney K.R., Chapron D.J., Brandt J.L., Gomolin I.H., Feig P.U., Kramer P.A. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin. Pharmacol. Ther. 1986 Nov;40(5):518–524. DOI: 10.1038/clpt.1986.217
29. Schwenk M.H., St Peter W.L., Meese M.G., Singhal P.C. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. Pharmacotherapy. 1995 JulAug;15(4):522–527. PMID: 7479208
30. Liu Y., Zhao J., Zhong X., Wei Q. and Huang Y. Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2019;10:679. DOI: 10.3389/fphar.2019.00679
31. Hong E., Ahn S., Lim H. The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. BMC Ophthalmol 2017 Jul 12;17(1):124. DOI: 10.1186/s12886-017-0517-0
32. Suzuki T., Hayakawa K., Nakagawa Y. Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal Clinical Ophthalmology 2013:7:549–553.
33. Kawai K., Ohashi H., Suzuki T., Kitagaki H., Fujisawa S. Effect of anti-glaucoma drugs on inflammatory cytokine production by human and murine peripheral blood mononuclear cells. Nippon Ganka Gakkai Zasshi. 2010;114:669–677 (In Japanese).
34. Wolfensberger T.J. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol. 1999;97:387–397.
35. Mirshahi A., Tadayoni R., Mohsenzadeh N. Efficacy of adjuvant topical timolol– dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study. J.Curr Ophthalmol. 2019 Jun;31(2):168–171. DOI: 10.1016/j.joco.2019.01.008
36. Kurysheva N.I., Azizova O.A., Piryazev A.P. Antiradical and antioxidant activity of carbonic anhydrase inhibitors for the local treatment of glaucoma. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(3):55–61 (In Russ.).
37. Kurysheva N.I., Azizova O.A. A comparative study of the antioxidant activity of combination drugs for the local treatment of glaucoma. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2013;6(2):48–51 (In Russ.).
38. Kurysheva N.I., Azizova O.A., Piryazev A.P. Antioxidant activity of a fixed combination of dorzolamide with timolol in the aspect of neuroprotection in glaucoma. Оphthalmology in Russia = Oftal’mologiya. 2012;9(4):47–51 (In Russ.). DOI: 10.18008/1816-5095-2012-4-47-51
39. Moreno V., Medina J., Pinazo R. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma Eur J Ophthalmol 2009;19(4):565–571. DOI: 10.1177/112067210901900408
40. Sacca S., La Maestra S., Micale R. Ability of dorzolamide hydrochloride and timolol maleate to target mitochondria in glaucoma therapy Arch Ophthalmol. 2011 Jan;129(1):48–55. DOI: 10.1001/archophthalmol.2010.324
41. Nocentini A., Ferraroni M., Carta F., Ceruso M., Gratteri P., Lanzi C. Benzenesulfonamides incorporating flexible triazole moieties are highly effective arbonic anhydrase inhibitors: synthesis and kinetic, crystallographic, computational, and intraocular pressure lowering investigations. J Med Chem 2016;59(23):10692–e10704. DOI: 10.1021/acs.jmedchem.6b01389
42. Long D.D., Frieman B., Hegde S.S., Hill C.M., Jiang L., Kintz S. A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939–e943. DOI: 10.1016/j.bmcl.2012.12.058
43. Chiaramonte N., Bua S., Ferraroni M., Nocentini A., Bonardi A., Bartolucci G. et al. 2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents. Eur J Med Chem 2018;151:363–e375. DOI: 10.1016/j.ejmech.2018.04.002
44. Steele R.M., Benedini F., Biondi S., Borghi V., Carzaniga L., Impagnatiello F., et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of openangle glaucoma. Bioorg Med Chem Lett 2009;19:6565–e6570. DOI: 10.1016/j.bmcl.2009.10.036
45. Haefliger I., Flammer J. Nitric Oxide and Endothelin in the Pathogenesis of Glaucoma, Survey of Ophthalmology, 1999;43(1):551–558. DOI: 10.1016/s0039-6257(99)00026-0
46. Kurysheva N.I. Eye hemoperfusion and glaucoma. Greenlight. 2014. 138 p. (In Russ.).
47. Kurysheva N.I., Tomilova I.K., Deev A.A., Nazarov S.B. Nitric oxide in the pathogenesis of cataracts and glaucoma. Annals of Ophthalmology = Vestnik oftal’mologii. 2001;5:5–7 (In Russ.).
48. Mincione F., Benedini F., Biondi S., Cecchi A., Temperini C., Formicola G. Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216– e3221. DOI: 10.1016/j.bmcl.2011.04.046
49. Fabrizi F., Mincione F., Somma T., Scozzafava G., Galassi F., Masini E. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzym Inhib Med Chem 2012;27:138–e147. DOI: 10.3109/14756366.2011.597749
50. Bozdag M., Altamimi A.S.A., Vullo D., Supuran C.T., Carta F. State of the art on carbonic anhydrase modulators for biomedical purposes. Curr Med Chem 2018;25. DOI: 10.2174/0929867325666180622120625
51. Carta F., Aggarwal M., Maresca A., Scozzafava A., McKenna R., Masini E., Supuran C.T. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo. J Med Chem 2012;55(4):1721–1730. DOI: 10.1021/jm300031j
Review
For citations:
Kurysheva N.I. Carbonic Anhydrase Inhibitors in the Treatment of Glaucoma. Review. Part II. Ophthalmology in Russia. 2020;17(4):676-682. (In Russ.) https://doi.org/10.18008/1816-5095-2020-4-676-682
Views:
2161
Email this article 